Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Elephant in the Room: Reckoning With Collegiality and Authorship in Academic Pharmacy.

American journal of pharmaceutical education·2026

Same author

As-Needed Medication Use for Agitation Across Valproic Acid Formulations.

Current therapeutic research, clinical and experimental·2026

Same author

Assessment of Curricular Integration of Compassionate Communication in Pharmacy Training.

American journal of pharmaceutical education·2026

Same author

Assessment of the Intestinal CYP3A Contribution to Drug Interactions with Extended-Release Tacrolimus (LCPT) Using Grapefruit Juice.

Clinical pharmacology in drug development·2026

Same author

Collaborative development of a shared objective structured clinical examination to assess the pharmacist patient care process across two PharmD programs.

Currents in pharmacy teaching & learning·2026

Same author

National trends in pharmacist and pharmacy technician suicide: Incidence and associated features.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026

Search research articles

Related Experiment Video

Updated: Jun 14, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Pharmacogenomics: bridging the gap between science and practice.

Kelly C Lee¹, Joseph D Ma, Grace M Kuo

¹Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093-0714, USA. kellylee@ucsd.edu

Journal of the American Pharmacists Association : Japha

|April 7, 2010

Summary

This summary is machine-generated.

Pharmacists are crucial for educating patients and professionals on pharmacogenomics, covering its principles, applications, and ethical considerations. A CDC-supported program aids this vital educational role.

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Related Experiment Videos

Last Updated: Jun 14, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Area of Science:

Pharmacogenomics and its integration into healthcare.
Ethical, social, and legal implications of genetic information in medicine.

Background:

Pharmacogenomics offers personalized medicine by linking genetic variations to drug responses.
Understanding pharmacogenomics is essential for optimizing therapeutic outcomes and minimizing adverse drug reactions.

Purpose of the Study:

To provide pharmacists with comprehensive knowledge of pharmacogenomics principles and clinical applications.
To highlight the social, ethical, and legal dimensions of pharmacogenomics.
To introduce a Centers for Disease Control and Prevention (CDC)-supported educational program for health professionals.

Main Methods:

Literature review encompassing PubMed, FDA recommendations, and professional guidelines.
Analysis of drug therapy in key areas like abacavir, SSRIs, tamoxifen, and warfarin.
Identification of challenges in clinical pharmacogenomics implementation.

Main Results:

Key pharmacogenomic concepts, including nomenclature and polymorphism types, were reviewed.
Clinical applications were demonstrated through examples in specific drug therapies.
Ethical, social, legal, and economic challenges to clinical translation were identified.

Conclusions:

Pharmacists are central to disseminating pharmacogenomics knowledge to patients and other healthcare providers.
An educational program has been developed to support evidence-based pharmacogenomics practice.